Expert Interview
A Third Look: Discussing Spruce Biosciences’ Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B
Ticker(s): SPRBInstitution: Cincinnati Children's Hospital Medical Center
- Professor of Clinical Pediatrics and Director of the Medical Genetics Residency and Fellowship Programam at Cincinnati Children's Hospital Medical Center.
- Currently manages 2 patients with with Sanfilippo Syndrome Type B (MPS IIIB) and 15 patients with late-onset pompe disease (LOPD) and has experience prescribing Nexviazyme.
- Research focuses on Fabry disease, Pompe disease, Sanfilippo Syndrome Type B (MPS IIIB), hypophosphatasia, velocardiofacial syndrome, 1p36 deletion syndrome, Neurofibromatosis type I, and other genetic conditions.
How many patients do you manage with Sanfilippo Syndrome Type B?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Spruce Biosciences’ Tralesinidase Alfa (TA-ERT) as a potential treatment for Sanfilippo Syndrome Type B?
Added By: lilly_adminWhat % of older patients that have progressed might not take this ERT? What prevalence of patients and what % of this disease will you think take this ERT in the US?
Added By: lilly_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
